Sam S. Chang MD, MBA (@urocancermd) 's Twitter Profile
Sam S. Chang MD, MBA

@urocancermd

Patricia and Rodes Hart Endowed Chair, Chief Surgical Officer, Vanderbilt Ingram Cancer Center

ID: 355233242

calendar_today15-08-2011 01:38:26

1,1K Tweet

4,4K Followers

1,1K Following

Vanderbilt Urology (@vumcurology) 's Twitter Profile Photo

Please join Vanderbilt Urology Urologic Oncology Society of Urologic Oncology Fellowship for Virtual Open House NEXT Tuesday! Learn about our high volume, opportunity-filled, collegial training program in the great city of #nashville YUO Link: redcap.vumc.org/surveys/?s=9WY…

Please join <a href="/VUMCurology/">Vanderbilt Urology</a> Urologic Oncology <a href="/UroOnc/">Society of Urologic Oncology</a>  Fellowship for Virtual Open House NEXT Tuesday! Learn about our high volume, opportunity-filled, collegial training program in the great city of #nashville <a href="/SUO_YUO/">YUO</a> 
Link: redcap.vumc.org/surveys/?s=9WY…
UroToday.com (@urotoday) 's Twitter Profile Photo

Current options for BCG unresponsive #NMIBC. Eugene Pietzak Memorial Sloan Kettering Cancer Center joins Sam S. Chang MD, MBA Vanderbilt Urology to discuss treatment options for BCG-unresponsive bladder cancer and the challenges of evaluating their comparative effectiveness. #WatchNow > bit.ly/3D5Ik2j

Society of Urologic Oncology (@uroonc) 's Twitter Profile Photo

Congratulations to Dr. Joseph A. Smith Jr. for being named the AUA 2025 Ramon Guiteras Award Recipient! To see more, please visit auanet.org/about-us/aua-g…

Dr. Pat Soon-Shiong (@drpatsoonshiong) 's Twitter Profile Photo

57 percent of urologists say they were not able to treat their patients with bladder cancer because Merck’s BCG is unavailable. Problem solved today!! #BCG. #bladdercancer Together with Anktiva we were able to show complete remission in bladder cancer patients now still disease

Sid S (@sid423) 's Twitter Profile Photo

1 whole year since my surgery to remove my tumor and left kidney that would lead to a #kidneycancer diagnosis. At 32 that wasn’t in my plans, but it happened. Although I had times of depression, and massive anxiety, I also met people who I will now call lifelong friends. I

1 whole year since my surgery to remove my tumor and left kidney that would lead to a #kidneycancer diagnosis. At 32 that wasn’t in my plans, but it happened. 

Although I had times of depression, and massive anxiety, I also met people who I will now call lifelong friends. I
ABU (@aburology) 's Twitter Profile Photo

🎉 Shoutout to ABU Oral Examiner Dr. Kelvin A. Moses, Associate Professor of Urology at Vanderbilt! His dedication to advancing urology & improving patient care is inspiring. 🙌 Thank you, Dr. Moses! Learn more about his work here: bit.ly/KelvinMoses #Urology #Inspiration

🎉 Shoutout to ABU Oral Examiner Dr. Kelvin A. Moses, Associate Professor of Urology at Vanderbilt! His dedication to advancing urology &amp; improving patient care is inspiring. 🙌 Thank you, Dr. Moses! Learn more about his work here: bit.ly/KelvinMoses #Urology #Inspiration
UroToday.com (@urotoday) 's Twitter Profile Photo

Development and initial experience of a dedicated female #BladderCancer clinical care coordinator role. Presentation by Bree Duncan, RN, BSN Vanderbilt Health. #SESAUA25 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3FwI6m3 Southeastern Section

Development and initial experience of a dedicated female #BladderCancer clinical care coordinator role. Presentation by Bree Duncan, RN, BSN <a href="/VUMChealth/">Vanderbilt Health</a>. #SESAUA25 written coverage by <a href="/zklaassen_md/">Zach Klaassen</a> <a href="/GACancerCenter/">Georgia Cancer Center</a> &gt; bit.ly/3FwI6m3 <a href="/SES_AUA/">Southeastern Section</a>
Sam S. Chang MD, MBA (@urocancermd) 's Twitter Profile Photo

Appreciate so much the support from Rich Kraemer and the Kraemer family. Bree has helped so many and her role hopefully can be a model for many to help our cancer patients

Appreciate so much the support from Rich Kraemer and the Kraemer family. Bree has helped so many and her role hopefully can be a model for many to help our cancer patients
UroToday.com (@urotoday) 's Twitter Profile Photo

Highlights from #SUO24! Amy Luckenbaugh Vanderbilt Health & Sam S. Chang MD, MBA Vanderbilt Urology dive into late-breaking #bladdercancer trials—combo intravesical gem/BCG for BCG-exposed & phase III cretostimogene in BCG-unresponsive CIS. Key takeaway? More options than ever for #NMIBC, with

Society of Urologic Oncology (@uroonc) 's Twitter Profile Photo

Thank you to all who came out to the SUO at AUA meeting in Vegas! Great meeting with so much information. We are now preparing for the Winter Meeting at the Sheraton Phoenix Downtown, Dec 2-5, 2025! Look forward to see you all there. suonet.org/meetings/event…

Alan Tan (@alantanmd) 's Twitter Profile Photo

Thanks UroToday.com grateful to work w Sam S. Chang MD, MBA, future is bright for patients as we incorporate highly effective ADC/IO combinations, sensitive and predictive biomarkers, novel intravesical tx leading to bladder preservation for more patients Bladder Cancer Advocacy Network

Katy Beckermann (@katy_beckermann) 's Twitter Profile Photo

Excited to join the World GU Conference, always a great way to hear expert insights and apply data to everyday care. Even better that it’s in my own backyard: Nashville! #WorldGU25 #GUonc #KidneyCancer #BladderCancer #ProstateCancer 🎸🎙️🧬📊

UroToday.com (@urotoday) 's Twitter Profile Photo

Perioperative systemic therapies for muscle-invasive #BladderCancer. Jacqueline Brown, MD Winship Cancer Institute of Emory University joins Sam S. Chang MD, MBA Vanderbilt Urology to discuss recent advances, including the #NIAGARA trial combining chemotherapy with durvalumab, and emerging data on antibody-drug conjugates

UroToday.com (@urotoday) 's Twitter Profile Photo

#BOND003 Cohort P results for BCG-unresponsive papillary bladder tumors. Mark Tyson Mayo Clinic joins Sam S. Chang MD, MBA Vanderbilt Urology discussing early results from BOND-003 Cohort P: 90.5% HG-RFS at 3 & 9 months with oncolytic immunotherapy cretostimogene. Well-tolerated & CIS-free

#BOND003 Cohort P results for BCG-unresponsive papillary bladder tumors. <a href="/MarkTysonMD/">Mark Tyson</a> <a href="/MayoClinic/">Mayo Clinic</a> joins <a href="/UroCancerMD/">Sam S. Chang MD, MBA</a> <a href="/VUMCurology/">Vanderbilt Urology</a> discussing early results from BOND-003 Cohort P: 90.5% HG-RFS at 3 &amp; 9 months with oncolytic immunotherapy cretostimogene. Well-tolerated &amp; CIS-free